Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.UK drug maker Shire has received an approvable letter from the FDA for Intuniv extended release tablets, a nonstimulant selective treatment for children and adolescents with attention-deficit hyperactivity disorder.
Subscribe to our email newsletter
Shire claims that unlike some other ADHD treatments, Intuniv is not a controlled substance and does not have a known mechanism for potential abuse or dependence.
“The information requested by the FDA was not unexpected, and Shire is working with the FDA to provide a full and timely response to the agency’s request,” the company said in a statement.
When approved, Intuniv will be the first medication indicated to treat ADHD symptoms by selectively targeting alpha-2A-receptors in the prefrontal cortex, an area of the brain that is thought to manage executive functioning tasks, according to Shire’s CEO, Matthew Emmens.